These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7577205)

  • 1. Economic evaluation of high-dose chemotherapy and bone marrow transplantation for patients with breast cancer of stage II or IIIA with more than 10 positive lymph nodes at surgical excision.
    Schulman KA; Glick HA
    J Natl Cancer Inst Monogr; 1995; (19):45-50. PubMed ID: 7577205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
    Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
    Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
    Bitran JD; Samuels B; Trujillo Y; Klein L; Schroeder L; Martinec J
    Clin Cancer Res; 1996 Sep; 2(9):1509-13. PubMed ID: 9816327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes.
    Lalisang RI; Hupperets PS; ten Haaft MA; Jansen RL; Schouten HC
    Bone Marrow Transplant; 1998 Feb; 21(3):243-7. PubMed ID: 9489646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer.
    Peters WP; Ross M; Vredenburgh JJ; Hussein A; Rubin P; Dukelow K; Cavanaugh C; Beauvais R; Kasprzak S
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):25-31. PubMed ID: 7916487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
    Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
    Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
    Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
    Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy (CTM) for breast cancer.
    Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
    Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer.
    Tallman MS; Rademaker AW; Jahnke L; Brown SG; Bauman A; Mangan C; Kelly C; Rubin H; Kies MS; Shaw J; Kiel K; Gordon LI; Gradishar WJ; Winter JN
    Bone Marrow Transplant; 1997 Nov; 20(9):721-9. PubMed ID: 9384473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
    Shi Y; Pan F; Han X
    Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: yes.
    Peters WP
    Important Adv Oncol; 1995; ():215-30. PubMed ID: 7672808
    [No Abstract]   [Full Text] [Related]  

  • 13. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy.
    Vredenburgh JJ; Peters WP; Rosner G; DeSombre K; Johnston WW; Kamel A; Wu K; Bast RC
    Bone Marrow Transplant; 1995 Dec; 16(6):815-21. PubMed ID: 8750275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
    Peters WP; Rosner GL; Vredenburgh JJ; Shpall EJ; Crump M; Richardson PG; Schuster MW; Marks LB; Cirrincione C; Norton L; Henderson IC; Schilsky RL; Hurd DD
    J Clin Oncol; 2005 Apr; 23(10):2191-200. PubMed ID: 15767638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy in breast cancer: out of favor but not out of promise.
    Glück S; Stewart D
    Bone Marrow Transplant; 2000 May; 25(10):1017-9. PubMed ID: 10828859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment.
    Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF
    Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out.
    Smith GA; Henderson IC
    Important Adv Oncol; 1995; ():201-14. PubMed ID: 7672807
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.
    Myers SE; Mick R; Williams SF
    Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: influence of clinical presentation on outcome.
    Geara FB; Nasr E; Tucker SL; Charafeddine M; Dabaja B; Eid T; Abbas J; Salem Z; Shamseddine A; Issa P; El Saghir N
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):364-9. PubMed ID: 17324529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.